Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissue

PLoS One. 2013 Sep 20;8(9):e76039. doi: 10.1371/journal.pone.0076039. eCollection 2013.

Abstract

Low-grade inflammation (LGI) is a central phenomenon in the genesis of obesity and insulin-resistance characterized by IL-6 in human serum. Whereas this LGI was initially thought to be mainly attributed to macrophage activation, it is now known that pre-adipocytes and adipocytes secrete several adipokines including IL-6 and participate to LGI and associated pathologies. In macrophages, HMGB1 is a nuclear yet secreted protein and acts as a cytokine to drive the production of inflammatory molecules through RAGE and TLR2/4. In this paper we tested the secretion of HMGB1 and the auto- and paracrine contribution to fat inflammation using the human preadipocyte cell line SW872 as a model. We showed that 1) human SW872 secreted actively HMGB1, 2) IL-6 production was positively linked to high levels of secreted HMGB1, 3) recombinant HMGB1 boosted IL-6 expression and this effect was mediated by the receptor RAGE and did not involve TLR2 or TLR4. These results suggest that HMGB1 is a major adipokine contributing to LGI implementation and maintenance, and can be considered as a target to develop news therapeutics in LGI associated pathologies such as obesity and type II diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / metabolism
  • Adipose Tissue / pathology*
  • Blotting, Western
  • Cell Proliferation
  • Chronic Disease
  • Enzyme-Linked Immunosorbent Assay
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • HMGB1 Protein / antagonists & inhibitors
  • HMGB1 Protein / genetics
  • HMGB1 Protein / metabolism*
  • Humans
  • Inflammation / metabolism
  • Inflammation / pathology*
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism*
  • Liposarcoma / genetics
  • Liposarcoma / metabolism*
  • Liposarcoma / pathology
  • RNA, Messenger / genetics
  • RNA, Small Interfering / genetics
  • Real-Time Polymerase Chain Reaction
  • Receptor for Advanced Glycation End Products / genetics
  • Receptor for Advanced Glycation End Products / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction
  • Toll-Like Receptor 2 / genetics
  • Toll-Like Receptor 2 / metabolism
  • Toll-Like Receptor 4 / genetics
  • Toll-Like Receptor 4 / metabolism
  • Tumor Cells, Cultured

Substances

  • HMGB1 Protein
  • HMGB1 protein, human
  • Interleukin-6
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptor for Advanced Glycation End Products
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4

Grants and funding

This work was supported by grants from CPER-FEDER GRII, University of La Réunion and the the “Structure Fédérative Environnement, Biodiversité, Santé” University of La La Réunion. BN holds a fellowship from the Biodiversité, Santé” Environnement, Biodiversité, Santé” University of La Réunion. MM and MKG hold fellowships from Regional Council of La Réunion. VGTH is a fellow from the French Ministry (contrat doctoral). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.